RxDoctor Payments Data

Harinder Bisla, MD

Internal Medicine · Roseville, CANPI 1174512685

Payments from drug & device makers

$4,444in general payments, 2019–2025

Across 249 payments — averaging $17.85 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$820
  • Novo Nordisk$516
  • GSK$491
  • AstraZeneca$331
  • Lilly USA, LLC$265
  • Boehringer Ingelheim$239
  • plus $2K from 36 others

What the payments were for

  • Food & beverage$4,34898%
  • Education$962%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,444 in reported general payments places this provider in the 85th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$671,233
Medicare patients
814
Services billed
8,011

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban73$101,908
OzempicSemaglutide61$99,805
JardianceEmpagliflozin26$39,182
JanuviaSitagliptin Phosphate28$34,052
MounjaroTirzepatide25$32,711
TradjentaLinagliptin24$22,239
MyrbetriqMirabegron13$16,397
LinzessLinaclotide20$14,600
SynthroidLevothyroxine Sodium151$9,736
Levothyroxine Sodium555$6,855
Lidocaine24$6,446
Rosuvastatin Calcium330$5,930
Dexlansoprazole DrDexlansoprazole18$5,428
PremarinEstrogens, Conjugated13$4,396
Ezetimibe84$4,223

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis, Premarin$217$106,30486 claims
Novo NordiskOzempic$516$99,80561 claims
Boehringer IngelheimJardiance, Tradjenta$239$61,42150 claims
MerckJanuvia$97$34,05228 claims
Lilly USA, LLCMounjaro$265$32,71125 claims
AbbVieLinzess, Synthroid, Armour Thyroid$820$26,960196 claims
Astellas Pharma US IncMyrbetriq$65$16,39713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Roseville

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →